Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00086632
Clinical Trial for Ovarian Cancer (OvaRex®)
Phase 3
Terminated
- Conditions
- First Posted Date
- 2002-12-06
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 354
- Registration Number
- NCT00050375
- Locations
- 🇺🇸
St. Jude Medical Center, Fullerton, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Univ. of Texas SW Medical Center at Dallas, Dallas, Texas, United States
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
Phase 2
Terminated
- Conditions
- First Posted Date
- 2002-04-29
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 102
- Registration Number
- NCT00034372
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇺🇸Parker Hill Oncology & Hematology, Boston, Massachusetts, United States
🇨🇦Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont, Fleurimont, Quebec, Canada
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Phase 1
Terminated
- Conditions
- First Posted Date
- 2002-04-24
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Unither Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00034138
- Locations
- 🇺🇸
Women's Cancer Research Foundation, Miami, Florida, United States
🇺🇸Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath